Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heiko Becker

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II TrialMichael Lübbert, Olga Grishina, Claudia Schmoor, et al.
Neuroendocrinology|May 20, 2026
Clinical impact of molecular tumor board inclusion on treatment outcomes in neuroendocrine neoplasmsMaryam Barsch, Linda Gräßel, Patrick Metzger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreGuido Marcucci, Pearlly Yan, Kati Maharry, et al.
European Journal of Haematology|October 14, 2024
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to DecitabineHelena Bresser, Claudia Schmoor, Olga Grishina, et al.
The Lancet. Haematology|November 1, 2023
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialMichael Lübbert, Pierre W Wijermans, Michal Kicinski, et al.
Cancers|April 3, 2021
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center AnalysisRouven Hoefflin, Adriana Lazarou, Maria Elena Hess, et al.
Science Translational Medicine|February 23, 2018
Oncogenic JAK2<sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasmsAlessandro Prestipino, Alica J Emhardt, Konrad Aumann, et al.
Science Immunology|October 8, 2021
The expansion of human T-bet<sup>high</sup>CD21<sup>low</sup> B cells is T cell dependentBaerbel Keller, Valentina Strohmeier, Ina Harder, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II TrialMichael Lübbert, Olga Grishina, Claudia Schmoor, et al.
Neuroendocrinology|May 20, 2026
Clinical impact of molecular tumor board inclusion on treatment outcomes in neuroendocrine neoplasmsMaryam Barsch, Linda Gräßel, Patrick Metzger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreGuido Marcucci, Pearlly Yan, Kati Maharry, et al.
European Journal of Haematology|October 14, 2024
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to DecitabineHelena Bresser, Claudia Schmoor, Olga Grishina, et al.
The Lancet. Haematology|November 1, 2023
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialMichael Lübbert, Pierre W Wijermans, Michal Kicinski, et al.
Cancers|April 3, 2021
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center AnalysisRouven Hoefflin, Adriana Lazarou, Maria Elena Hess, et al.
Science Translational Medicine|February 23, 2018
Oncogenic JAK2<sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasmsAlessandro Prestipino, Alica J Emhardt, Konrad Aumann, et al.
Science Immunology|October 8, 2021
The expansion of human T-bet<sup>high</sup>CD21<sup>low</sup> B cells is T cell dependentBaerbel Keller, Valentina Strohmeier, Ina Harder, et al.
Pageof 10